 |
|
|
| |
Peginterferon alfa-2a (180 μg/48 weeks) is well tolerated with high rates of treatment adherence: results of the NEPTUNE study
|
| |
| |
Reported by Jules Levin
Presented at The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011), 17-20 February 2011, Bangkok, Thailand
J Jia, KH Han, HLY Chan, T Piratvisuth, Y Cui, C Wat, WL Chuang, Y-F Liaw
Beijing Friendship Hospital, Capital Medical University, Beijing
|
| |
|
|
|
|
|
